Several models of DC therapy for cancer have been proposed. The models include mDCs expressing cytokines by gene-transfection, mDCs loading tumor antigens and mDCs stimulated by adjuvants such as TLR ligands. The effectiveness of mDC therapies has been tested in animals, and some of them have been evaluated for clinical applications.
These studies encouraged us to establish methods for inducing tumor-specific CTL responses and reciprocal activation of NK cells.
In this communication, we generated mouse mDCs that constitutively express MyD88 Four plasmids (one of these pLenti vectors, pLP1, pLP2, pLP/VSVG) were transfected into 293FT packaging cells, and the viral particles for transfection were prepared according to the manufacturer's protocol. The virus particles were concentrated by centrifugation of 20,000 rpm at 4 ˚C for 2 hrs. After the precipitation was resuspended in RPMI1640 as the virus concentrated solution, the solution was subdivided to store at -80 ˚C.
Transfection efficiency
The transfection efficiency was assessed by fluorescence of GFP ligated in the vector of the lentivirus, and the rate of the positive cell was determined by FACS in comparison with that of non-infected cells. The indicated volume of virus concentrated solution was added to 293FT cells (5x10^5 cell/500 μl of culture medium with 5 μg/ml polybrene (Specially Media, Phillipsburg, NJ ) in 24 well plate) and incubated for 12 hrs.
These cells were cultured for 36 hrs additionally in fresh medium after wash. Then, the fluorescence intensities of the cells were assessed by FACS. Transduction efficiency of mDCs were analyzed under the same conditions as that of 293FT cells.
MLR assay.
Mouse mDCs were derived form bone marrow of C57BL6 and appropriately manipulated as described in the text. mDCs (5 x 10^4 cells) were cultured with 10^5 CD90-positive T cells isolated from spleen of BALB/c mice by MACS beads in 96-well cell culture plates in 200 μl of culture medium for 72 hrs. Half of the medium was replaced with fresh medium containing [3H]-thymidine (1 μCi/well). Then the cells and medium were harvested separately using a cell harvester, and the radioactivity was measured by MicroBeta (Perkin Elmer, Foster City, CA) with solid scintillator.
Preparation of mouse bone marrow-derived mDCs
Wild-type female C57BL/6 and BALB/c mice were purchased from Japan Clea (Tokyo, Japan). Bone marrow-derived mDCs were prepared as reported (27) with minor modifications. mDCs were cultured in RPMI-1640 containing 10 ng/ml mouse GM-CSF, 50 μM 2-ME, 10 mM HEPES and 10% FCS. 
Dendritic cell (DC) therapy
The protocol of animal studies is shown in Figure 4a . The doses of virus preparations were adjusted by titration assay to make 50% of 293FT cells GFP positive (ED50). The ED50 doses of virus were cultured with mouse mDCs for 12 hrs as in the conditions employed for 293FT cells (5 x 10^5cells/500 μl in a 24-well plate). mDCs were then washed and suspended in fresh culture medium for additional culture for 12 hrs (total 24 hrs). Tumor debris was prepared from B16 cells by 3-cycle freeze-thaw and the B16 debris 
Cytotoxic assay
Debris of B16D8 cells (10^6 cells) was prepared by freeze-thaw for immunization.
C57BL/6 mice were subcutaneously immunized with the debris twice on day -14 and -7. On day 0, the mice were sacrificed and CD8+ splenocytes (containing CTL and part of NK) were We also examined the production of cytokines or IFNs by mDCs transduced with MyD88 or TICAM-1 since cytokine/IFN are possible maturation markers for mDCs.
High levels of IL-6 and IL12p40 were predominantly detected in the culture supernatants of MyD88-expressing mDCs (Figures 3a, b) , whereas the production of IFN-α was augmented in the culture supernatant of TICAM-1-expressing mDCs (Figure 3c ). In the MLR experiment, no large difference between these two mDCs was observed. In mDCs expressing either MyD88 or TICAM-1, MLR was slightly augmented compared to the mock-infected mDCs (Figure 3d ).
mDCs transduced with the TLR adaptor gene were employed as a DC therapy for cancer in a mouse model, and the therapeutic effect of the mDCs on tumor regression was examined. The schedule of mDC manipulation/therapy is shown in Fig. 4a . The manipulated mDCs retarded the growth of implanted tumors (Figure 4b ). This antitumor effect was negligible in the control group consisting of mDCs infected with control virus.
However, an antitumor effect was observed in the group consisting of mDCs that expressed the TICAM-1 N terminal region. Furthermore, the group consisting of mDCs transfected with MyD88 triggered a more significant retardation of tumor growth than the group consisting of mDCs transfected with TICAM-1.
We tested whether the adaptor-transduced mDCs augment antigen-dependent or Here, we propose a method for specifically activating mDCs by introducing TLR adaptor molecules into mouse mDCs using a lentivirus vector. The differential activation phenotype was obtained depending on the adaptor employed. CD86 was up-regulated in mDCs expressing TICAM-1 but not in mDCs expressing MyD88. MyD88 allowed mDCs to induce IL-6 and IL12p40 and augmented MLR, whereas TICAM-1 (N-terminal) facilitated mDCs by potentially inducing type I IFN and augmenting MLR.
Perhaps, the MLR activity does not always reflect in vivo antitumor activity: MyD88 preferentially matures mDCs with ability to induce antigen-dependent lymphocyte-mediated cytotoxicity whereas TICAM-1 matures mDCs to induce NK-like cytotoxicity. Either of these mDCs exhibited in vivo tumor-regression activity irrespective of their phenotypic differences. Hence, the level of CD86 does not always reflect the antitumor potency of mDCs.
Although the retardation of tumor growth was significant in this mDC adoptive-transfer therapy, we observed low protein-expression efficacy (~50%) and apoptosis-inducing properties of mDCs. Since these technical problems were particularly prominent in TICAM-1-expressing mDCs, we employed the TICAM-1 N-terminal construct. Regardless of these technical problems, TICAM-1 N-terminal confers unique properties on mDCs, which are consistent with previous reports using the full-length TICAM-1, suggesting that polyI:C-mediated TLR3 activation results in cross-priming and mDC-mediated NK activation (30, 31) . The antitumor potential due to activation of the TLR3-TICAM-1 pathway may be closely linked to mDC-mediated NK activation.
Our previous findings using TLR adaptor gene-knock out mice indicated that in mDCs, the TICAM-1 pathway is involved in NK activation (13) , while the MyD88 pathway solely induces CTL resulting in tumor regression (12) . We obtained these results using and parental B16 melanoma (data not shown).
The functional interpretation of the data for mDCs over-expressing MyD88 is more complicated. Since MyD88 is an adaptor molecule of not only the TLR but also IL-1 and IL-18 receptors (3, 4) , mDCs expressing MyD88 are implicated in more complex inflammatory reactions. Consistent with this, adoptive transfer of MyD88-expressing mDCs induced a superior antitumor effect than TICAM-1-expressing mDCs. However, since no appropriate method for determining CTL activity in the lentiviral mDC manipulation system, we were unable to detect the antitumor CTL activity generated in mice receiving DC therapy (data not shown).
The lentivirus vector is an efficient tool for gene delivery into differentiated cells (33) . Potent protective immunity has been induced by administration of tumor RNA-pulsed mDCs (35) . An effective therapeutic potential has been obtained using mDCs with a modified IL-12 gene (36). These last two reports suggest that the intratumoral route is more effective than the other extratumoral routes (35, 36) . Here, we propose a strategy of specifying the mode of maturation of mDCs by manipulating TLR signaling. It is possible that a more effective therapeutic gain is obtained by further revision of our administering protocol, schedule, route, and the number of mDCs used.
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